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The human amniotic fluid stem cell 
secretome effectively counteracts 
doxorubicin-induced cardiotoxicity
Edoardo Lazzarini1,*, Carolina Balbi2,*, Paola Altieri1, Ulrich Pfeffer3, Elisa Gambini4, 
Marco Canepa1, Luigi Varesio5, Maria Carla Bosco5, Domenico Coviello6, Giulio Pompilio4, 
Claudio Brunelli1, Ranieri Cancedda2, Pietro Ameri1,† & Sveva Bollini2,†
The anthracycline doxorubicin (Dox) is widely used in oncology, but it may cause a cardiomyopathy with 
bleak prognosis that cannot be effectively prevented. The secretome of human amniotic fluid-derived 
stem cells (hAFS) has previously been demonstrated to significantly reduce ischemic cardiac damage. 
Here it is shown that, following hypoxic preconditioning, hAFS conditioned medium (hAFS-CM) 
antagonizes senescence and apoptosis of cardiomyocytes and cardiac progenitor cells, two major 
features of Dox cardiotoxicity. Mechanistic studies with mouse neonatal ventricular cardiomyocytes 
(mNVCM) reveal that hAFS-CM inhibition of Dox-elicited senescence and apoptosis is associated with 
decreased DNA damage, nuclear translocation of NF-kB, and upregulation of the NF-kB controlled 
genes, Il6 and Cxcl1, promoting mNVCM survival. Furthermore, hAFS-CM induces expression of the 
efflux transporter, Abcb1b, and Dox extrusion from mNVCM. The PI3K/Akt signaling cascade, upstream 
of NF-kB, is potently activated by hAFS-CM and pre-treatment with a PI3K inhibitor abrogates NF-kB 
accumulation into the nucleus, modulation of Il6, Cxcl1 and Abcb1b, and prevention of Dox-initiated 
senescence and apoptosis in response to hAFS-CM. These results support the concept that hAFS are a 
valuable source of cardioprotective factors and lay the foundations for the development of a stem cell-
based paracrine treatment of chemotherapy-related cardiotoxicity.
Anthracyclines, especially doxorubicin (Dox), are the mainstay of treatment for several types of cancer. Their 
main side effect is cardiotoxicity, which most often presents as left ventricular dysfunction or heart failure with 
delayed onset1,2. In fact, many years can elapse between anthracycline administration and the appearance of 
anthracycline-related cardiomyopathy. Nevertheless, morbidity and mortality of heart failure secondary to anth-
racycline exposure may impact prognosis even more than the tumour for which chemotherapy was originally 
given. This scenario is currently quite common for some types of cancer, such as of the breast, and it will become 
more frequent in the future, as survival of oncological patients steadily increases with improved efficacy of anti-
cancer therapies. Anthracycline cardiotoxicity may be particularly relevant for paediatric patients treated for hae-
matological or solid tumours, since cardiomyopathy may develop over a long period of time and yet cause heart 
failure at a relatively young age3,4. Remarkably, clinical surveillance of patients whose cancers have been cured, or 
are in stable remission, is often loose and cardiac disease may remain unrecognized5. Thus, anthracycline cardio-
myopathy is an extremely relevant medical issue with insidious evolution and growing incidence.
Unfortunately, to date no effective means exists to antagonize anthracycline cardiotoxicity6. Beta-blockers 
and angiotensin-converting enzyme inhibitors, which are well-known to reduce cardiac remodelling, have been 
shown to confer some protection, but it may be non-specifically due to the antagonism of maladaptive neurohor-
monal feedbacks. In addition, these medications are not always effective, with normalization of left ventricular 
ejection fraction being reported in only 11% of patients facing anthracycline cardiotoxicity7. On the other hand, 
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the iron chelator dexrazoxane opposes key events in the pathogenesis of anthracycline cardiac toxicity, but there 
are concerns that it may limit the efficacy of anticancer drugs5,6.
Against this background, new strategies to tackle anthracycline cardiotoxicity are urgently needed. Most 
knowledge about the pathogenesis of anthracycline-induced heart disease comes from studies with Dox. It has 
been demonstrated that senescence8 and apoptosis9 of cardiomyocytes and cardiac progenitor cells (CPC) under-
lie Dox cardiomyopathy. At the subcellular level, Dox primarily interferes with topoisomerase-IIβ and causes 
DNA damage, followed by a DNA damage response and a cascade of perturbations culminating in cell cycle arrest 
or death10. Therefore, the ideal intervention to prevent Dox cardiotoxicity should limit DNA damage and elicit 
anti-senescent and anti-apoptotic pathways in cardiomyocytes and CPC.
Here, we demonstrate that the secretome (i.e. the entire set of paracrine factors secreted by cells) of human 
amniotic fluid-derived stem cells (hAFS) has such a profile of activity. hAFS are broadly multipotent mesenchy-
mal progenitors isolated upon c-kit expression from the heterogeneous cell population contained in leftover 
samples of second trimester amniotic fluid, obtained by amniocentesis for routine prenatal screening11. They are 
endowed with both high self-renewal potential and embryonic stem cell-like properties and secrete regenerative 
paracrine factors which have been shown to stimulate neo-arteriogenesis, recruit host progenitor cells in vivo, 
and promote tissue regeneration in different injury models12,13. It is noteworthy that hAFS conditioned medium 
(hAFS-CM), which contains all the bioactive molecules secreted by the cells, has already been reported to con-
siderably reduce cardiac ischemic damage in the short time in a rat model by exerting paracrine anti-apoptotic 
effects on resident cardiomyocytes14. Moreover, harvesting of hAFS from leftover samples of amniotic fluid col-
lected for prenatal screening does not carry any clinically unnecessary risk of harm for either the mother or the 
foetus, nor does it raise ethical concerns. Therefore, in this study we suggest harnessing the hAFS secretome to 
antagonize the cardiotoxic side effects of Dox for future paracrine therapy.
Results
The hAFS secretome rescues H9c2 cells from Dox-induced senescence and apoptosis. An estab-
lished in vitro model of Dox cardiotoxicity15,16 was initially used to screen the effects of the hAFS-CM. H9c2 rat 
embryonic cardiomyoblasts were exposed to Dox with or without prior incubation with the hAFS-CM obtained 
by culturing hAFS under normoxic (20% O2) or hypoxic (1% O2) conditions (hAFS-CMNormo and hAFS-CMHypo, 
respectively). Since we previously observed that hAFS are activated by the ischemic environment and promote 
cardiomyocyte survival in a paracrine manner14, hypoxic preconditioning was used as a working strategy to 
enrich hAFS-CM for cardioprotective factors. Indeed, hAFS-CMHypo showed an almost two-fold increase in pro-
tein concentration compared to hAFS-CMNormo (485.1 ± 67.1 μ g/106 cells versus 266.6 ± 35.2 μ g/106 cells, respec-
tively; see Supplementary Fig. S1). As shown in Fig. 1, the percentage of cells stained for senescence associated 
(SA) β -galactosidase16 (Fig. 1a,b) and cleaved caspase-3 (Fig. 1c,d) dramatically rose with Dox to values similar 
to those found previously15,16 and was significantly reduced by 35% and 26%, respectively, by pre-treatment with 
hAFS-CMNormo (46.5 ± 1.7% vs 30.4 ± 4.5% of SA β -galactosidase positive cells and 25.0 ± 1.0% vs 18.5 ± 0.8% 
cleaved caspase-3 positive cells). The hAFS-CMHypo was even more protective, the number of senescent and apop-
totic cells being decreased by 49% and 43% respectively (46.5 ± 1.7% vs 23.7 ± 1.8% of β -galactosidase positive 
cells and 25.0 ± 1.0% vs 14.2 ± 1.4% cleaved caspase-3 positive cells).
By contrast, Dox-elicited senescence and apoptosis were not reduced by pre-incubation with the conditioned 
medium from the human keratinocyte cell line, NCTC 2544 (hNCTC-CMNormo and hNCTC-CMHypo), used as an 
internal control (Fig. 1b,c). Compared with untreated cells, no significant change in SA β -galactosidase or cleaved 
caspase-3 expression was seen when incubating H9c2 cardiomyoblasts with the hAFS-CMNormo or hAFS-CMHypo 
alone (see Supplementary Fig. S2).
hAFS-CMHypo effectively protects mouse neonatal cardiomyocytes against Dox. Next, the car-
dioprotective potential of hAFS-CMHypo - which had proved to be the most effective form of hAFS-CM to pre-
vent Dox toxicity in the experiments with H9c2 cardiomyoblasts - was confirmed on primary mouse neonatal 
ventricular cardiomyocytes (mNVCM). Consistent with earlier studies16, SA β -galactosidase positive mNVCM 
were about 45% after Dox treatment. Pre-incubation with hAFS-CMHypo diminished the frequency of senescent 
cells by 47% (Fig. 2a,b: upper panel; 44.7 ± 2.9% vs 23.6 ± 2.4% of SA β -galactosidase positive cells). Similar 
results were obtained by immunostaining for p16INK4a, with the hAFS-CMHypo decreasing the pro-senescent effect 
of Dox by 35% (Fig. 2b lower panel; 48.8 ± 1.8% vs 31.8 ± 1.5% of p16INK4a positive cells). Moreover, there were 
twice as many cleaved caspase-3 positive cells with Dox as without treatment, and this increase in apoptosis 
was also reduced by the hAFS-CMHypo by 41% (Fig. 2c,e: 41.6 ± 2.1% vs 24.7 ± 1.1% cleaved caspase-3 positive 
cells). Correspondingly, cell viability, as measured by MTT assay, was increased by 10.5% by pre-incubation with 
hAFS-CMHypo (Fig. 2d,f). Importantly, hNCTC-CM did not prevent Dox-initiated senescence and apoptosis of 
mNVCM (Fig. 2b,e,f), nor were these cell responses significantly modified by hAFS-CMHypo or hAFS-CMNormo 
alone (see Supplementary Fig. S2).
Immunoreactivity for phosphorylated H2AX (γ H2AX), a sensitive indicator of DNA double-strand breaks 
and damage17, was much more widespread and intense following exposure to Dox, than in untreated mNVCM 
(Fig. 2g). Mean fluorescence intensity for γ H2AX was increased by about 4-fold by Dox compared to untreated 
cells, but limited to a 2.4 fold change, corresponding to a 37% reduction, by pre-incubation with the hAFS-CM 
(Fig. 2g, right panel).
hAFS-CMHypo acts through the NFkB-controlled pro-survival genes Il6 and Cxcl1 and the PI3K/
Akt pathway. To identify the pathways responsible for hAFS-CMHypo antagonism of Dox cardiotoxicity, 
gene expression profiles were compared between mNVCM treated with Dox or incubated with hAFS-CMHypo 
followed by Dox exposure. Microarray analysis using Affymetrix technology revealed that pre-treatment with 
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hAFS-CMHypo led to the up-regulation of genes coding for cytokines, chemokines, growth factors, and chemokine 
and cytokine receptor binding proteins (Fig. 3a and Supplementary Table S1). In particular, Il6 and Cxcl1 were 
highly expressed. Confirmatory real time qRT-PCR at 6 hours after Dox treatment demonstrated that these two 
genes were up-regulated by 7 and 29 fold compared to untreated cells and by 17- and 59 fold compared to Dox 
treatment, respectively, when the hAFS-CMHypo preceded Dox exposure (Fig. 3b). Since IL-6 and CXCL-1 have 
been shown to be involved in mNVCM survival18,19, we investigated whether blockade of these two cytokines 
might influence the protective effects of hAFS-CMHypo. The decrease in apoptosis attained with hAFS-CMHypo 
was significantly blunted when pre-incubation with hAFS-CMHypo was followed by treatment with Dox, along 
with antibodies against IL-6 or IL-6 as well as CXCL-1 (either soon after or after 6 hours post Dox administra-
tion, Fig. 3c), thus indicating that hAFS-CMHypo inhibits Dox-induced apoptosis via IL-6 and, to a lesser extent, 
CXCL-1.
Il6 and Cxcl1 are controlled by nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κ B). Under 
basal conditions, the latter is kept inactive in the cytoplasm by inhibitor of κ B alpha (Iκ Bα ). Phosphorylation of 
Iκ Bα at critical serine residues leads to its degradation and relieves NF-κ B, which can localize to the nucleus and 
modulate the transcription of target genes. Consistently, pre-incubation of mNVCM with hAFS-CMHypo before 
Dox treatment enhanced Iκ Bα phosphorylation (Fig. 4a) and increased the amount of NF-κ B in the nuclear 
compartment, as assessed by ELISA for the p65 subunit (Fig. 4b), although not to a statistically significant extent. 
Since the phosphoinositide 3-kinase (PI3K)/Akt cascade is a main trigger of Iκ Bα degradation, we sought to 
determine whether this pathway lies upstream of the activation of NF-κ B, the induction of Il6 and Cxcl1, and the 
Figure 1. The hAFS-CM inhibits the pro-senescent and pro-apoptotic effect of Dox on H9c2 cells.  
(a) Representative images of rat H9c2 cardiomyoblasts stained for senescence associated (SA) β -galactosidase: 
untreated cells (Ctrl), cells exposed to 0.1 μ M Dox (Dox), and cells pre-incubated with 40 μ g/ml of: the 
hAFS-CMNormo (hAFS-CMNormo + Dox), the hAFS-CMHypo (hAFS-CMHypo + Dox), the hNCTC-CMNormo 
(hNCTC-CMNormo + Dox), or the hNCTC-CMHypo (hNCTC-CMNormo + Dox) prior to Dox treatment. Scale bar 
100 μm. (b) Percentage of H9c2 cells expressing SA β -galactosidase after exposure to Dox with or without pre-
incubation with 40 μ g/ml of the hAFS-CM or hNCTC-CM (mean ± s.e.m.). Ctrl: 11.7 ± 1.2%, Dox: 46.5 ± 1.7%, 
hAFS-CMNormo + Dox: 30.4 ± 4.5%, hAFS-CMHypo + Dox: 23.7 ± 1.8%, hNCTC-CMNormo + Dox: 46.9 ± 1.2%, 
and hNCTC-CMHypo + Dox: 46.4 ± 3.3%; * * * p < 0.001 (p = 0.0004), * * * * p < 0.0001. (c) Representative 
images of H9c2 cardiomyoblasts stained for cleaved caspase-3 (Caspase-3): untreated cells (Ctrl), cells exposed 
to 1 μ M Dox (Dox), and cells pre-incubated with 40 μ g/ml of: the hAFS-CMNormo (hAFS-CMNormo + Dox), the 
hAFS-CMHypo (hAFS-CMHypo + Dox), the hNCTC-CMNormo (hNCTC-CMNormo + Dox), or the hNCTC-CMHypo 
(hNCTC-CMNormo + Dox) prior to Dox treatment. Scale bar 100 μ m. (d) Percentage of H9c2 cells expressing 
cleaved caspase-3 (% Caspase-3+ cells) after exposure to Dox with or without pre-incubation with 40 μ g/ml 
of the hAFS-CM or hNCTC-CM (mean ± s.e.m.). Ctrl: 1.1 ± 0.2%, Dox: 25.0 ± 1.1%, hAFS-CMNormo + Dox: 
18.5 ± 0.8%, hAFS-CMHypo + Dox: 14.2 ± 1.4%, hNCTC-CMNormo + Dox: 32.0 ± 3.9%, and hNCTC-CMHypo + 
Dox: 28.3 ± 1.7%; * p < 0.05 (p = 0.0433), * * p < 0.01 (p = 0.0014).
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Figure 2. The hAFS-CMHypo is endowed with paracrine cardioprotective properties against Dox damage. 
(a) Representative images of mNVCM stained for senescence associated (SA) β -galactosidase: untreated cells 
(Ctrl), cells exposed to 0.2 μ M Dox (Dox), and cells pre-incubated with 40 μ g/ml of hAFS-CMHypo (hAFS-CMHypo 
+ Dox) or hNCTC-CMHypo (hNCTC-CMNormo + Dox). Scale bar 100 μ m. (b) Upper panel: mNVCM expressing 
SA β -galactosidase after Dox exposure with or without pre-incubation with 40 μ g/ml of the hAFS-CMHypo or 
the hNCTC-CMHypo (mean ± s.e.m.). Ctrl: 16.4 ± 1.9%, Dox: 44.7 ± 2.9%, hAFS-CMHypo + Dox: 23.6 ± 2.4%, 
and hNCTC-CMHypo + Dox: 40.5 ± 10.2%; * * * * p < 0.0001. Lower panel: mNVCM expressing p16INK4a after 
Dox treatment with or without pre-incubation with 40 μ g/ml of the hAFS-CMHypo or the hNCTC-CMHypo 
(mean ± s.e.m.). Ctrl: 14.5 ± 2.9%, Dox: 48.8 ± 1.8%, hAFS-CMHypo + Dox: 31.8 ± 1.5%, and hNCTC-CMHypo 
+ Dox: 41.9 ± 3.0%; * * * * p < 0.0001. (c) Representative images of mNVCM stained for cleaved caspase-3 
(Caspase-3): untreated cells (Ctrl), cells exposed to 1 μ M Dox (Dox), and cells pre-incubated with the hAFS-
CMHypo (hAFS-CMHypo + Dox) or the hNCTC-CMHypo (hNCTC-CMNormo + Dox). Scale bar 100 μ m.  
(d) Representative images of viable mNVCM by MTT assay: untreated cells (Ctrl), cells exposed to 1 μ M Dox 
(Dox), and cells pre-incubated with the hAFS-CMHypo (hAFS-CMHypo + Dox) or the hNCTC-CMHypo (hNCTC-
CMNormo + Dox) prior to Dox. Scale bar 100 μ m. (e) mNVCM expressing cleaved-caspase-3 (% Caspase-3+ cells) 
after exposure to Dox with or without pre-incubation with 40 μ g/ml of the hAFS-CMHypo or the hNCTC-CMHypo 
(mean ± s.e.m.). Ctrl: 17.3 ± 0.8%, Dox: 41.6 ± 2.1%, hAFS-CMHypo + Dox: 24.7 ± 1.1%, and hNCTC-CMHypo + 
Dox: 41.5 ± 4.1%; * * * * p < 0.0001. (f) Percentage of viable mNVCM by MTT assay, after exposure to Dox with 
or without pre-incubation with 40 μ g/ml of the hAFS-CMHypo or hNCTC-CMHypo, compared to untreated cells 
(mean ± s.e.m.). Ctrl: 100%, Dox: 80.0 ± 0.8%, hAFS-CMHypo + Dox: 90.5 ± 2.1%, and hNCTC-CMHypo + Dox: 
77.8 ± 1.4%; * * p < 0.01 (p = 0.006). (g) Representative images of mNVCM stained for γ H2AX: untreated cells 
(Ctrl), cells exposed to 1 μ M Dox (Dox), and cells pre-incubated with 40 μ g/ml of the hAFS-CMHypo (hAFS-CMHypo 
+ Dox). Scale bar 20 μ m. The graph on the right shows the mean fluorescence intensity (MFI) fold change after 
exposure to Dox, with or without pre-incubation with the hAFS-CMHypo; * p < 0.05 (p = 0.0114).
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protection against Dox toxicity by the hAFS-CMHypo. The PI3K inhibitor, LY-294002, reduced the phosphoryla-
tion of Iκ Bα (Fig. 4a), prevented the nuclear accumulation of NF-κ B (Fig. 4b), and attenuated the increase in Il6 
and Cxcl1 (Fig. 4c). Furthermore, it abolished the inhibition of Dox-triggered senescence and apoptosis attained 
with the hAFS-CMHypo (Fig. 4d), indicating that hAFS-CMHypo up-regulates the NF-κ B-dependent pro-survival 
genes, Il6 and Cxcl1, and counteracts Dox cardiotoxicity at least in part via PI3K/Akt. In fact, AFS-CMHypo 
potently stimulated the phosphorylation of Akt twice as much compared to Dox treatment alone, an effect which 
was abrogated by LY-294002 (Fig. 4e).
Figure 3. The pro-survival genes Il6 and Cxcl1 are up-regulated by incubation with the hAFS-CMHypo 
prior to Dox exposure and play a pivotal role in hAFS-CMHypo cardioprotection. (a) Schematic illustrating 
the cluster of genes coding for cytokines, chemokines, growth factors, and chemokine and cytokine receptor-
binding proteins up-regulated by incubation with 40 μ g/ml of hAFS-CMHypo prior to exposure to 1 μ Μ Dox, 
according to microarray analysis. (b) Real time qRT-PCR showing significant up-regulation of the NF-κ B- 
controlled pro-survival genes Il6 and Cxcl1 in mNVCM incubated with 40ug/ml of hAFS-CMHypo prior to 
treatment with 1 μ M Dox; * * p < 0.01 (p = 0.0015 and p = 0.0020, respectively). (c) Percentage of mNVCM 
expressing cleaved caspase-3 (% Caspase-3+ cells) after exposure to Dox, with or without pre-incubation 
with 40 μ g/ml of the hAFS-CMHypo and with blocking antibodies against IL-6 (anti-IL6) and/or CXCL-1 
(anti-CXCL1) added to the culture medium (mean ± s.e.m.). Ctrl: 18.55 ± 4.0%, Dox: 42.57 ± 7.7%, hAFS-
CMHypo + Dox: 25.25 ± 3.5%, The following values refer to results obtained adding blocking antibodies when 
Dox treatment began, after 3 hours of incubation with the hAFS-CM: hAFS-CMHypo + Dox + anti-IL-6: 
42.79 ± 2.7%, hAFS-CMHypo + Dox + anti-CXCL-1: 37.94 ± 1.8%, hAFS-CMHypo + Dox + anti-IL-6 and+ 
anti-CXCL-1: 39.68 ± 9.1%, * * * * p < 0.0001, * * * p < 0.001 (p = 0.0002), * * p < 0.01 (p = 0.0041) * p < 0.05 
(p = 0.0181). The following values refer to results obtained adding blocking antibodies 6 and 9 hours after Dox 
treatment and hAFS-CM incubation, respectively: hAFS-CMHypo + Dox + anti-IL-6: 41.75 ± 1.1%, hAFS-
CMHypo + Dox + anti-CXCL-1: 34.83 ± 7.1%, hAFS-CMHypo + Dox + anti-IL-6 + anti-CXCL-1: 41.75 ± 5.1%; 
* * * p < 0.001 (p = 0.0006).
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Figure 4. hAFS-CMHypo prevention of Dox cardiotoxicity is associated with activation of the PI3K/Akt 
and NF-κB pathways. (a) Western blot analysis for the expression of phosphorylated Iκ Bα (Ser32/36 p-Iκ 
Bα, 40kDa) in untreated mNVCM or mNVCM treated with 1 μ M Dox, with 40 μ g/ml hAFS-CMHypo prior to 
exposure to 1 μ M Dox, or with 20 μ M LY-294002 (PI3K inhibitor) followed by 40 μ g/ml hAFS-CMHypo and 1 μM 
Dox. Full-length blots are represented in Supplementary Fig. S4. (b) ELISA analysis for nuclear expression of 
the p65 subunit of the NF-kB complex in untreated mNVCM (Ctrl) or mNVCM treated with 1 μ M Dox (Dox), 
with 40 μ g/ml hAFS-CMHypo followed by 1 μ M Dox (hAFS-CMHypo + Dox), or with 40 μ g/ml hAFS-CMHypo 
followed by 1 μ M Dox after pre-incubation with 20 μ M LY-294002 (LY-294002 + hAFS-CMHypo + Dox). Pg: 
picogram; μ g: microgram. (c) Real time qRT-PCR showing that treatment of mNVCM with 20 μ M LY-294002 
(LY-294002 + hAFS-CMHypo + Dox) also abrogated the upregulation of Il6 and decreased that of Cxcl1 attained 
by pre-incubation with 40 μ g/ml hAFS-CMHypo prior to exposure to 1 μ M Dox (hAFS-CMHypo + Dox). * p < 0.05 
(p = 0.0309 and p = 0.0324, for Il6 and Cxcl1 respectively), * * p < 0.01 (p = 0.0015), * * * p < 0.001 (p = 0.0006). 
(d) Percentage of mNVCM expressing SA β -galactosidase (upper panel) and cleaved caspase-3 (% Caspase-3+ 
cells, lower panel): untreated cells (Ctrl), cells exposed to 1 μ M Dox (Dox), and cells treated with 40 μ g/ml 
hAFS-CMHypo followed by 1 μ M Dox (hAFS-CMHypo + Dox) or with 40 μ g/ml hAFS-CMHypo followed by 1 μM 
Dox after pre-incubation with 20 μ M LY-294002 (LY-294002 + hAFS-CMHypo + Dox). Note the reversion 
of the cardioprotective effects of the hAFS secretome with LY-294002 (LY-294002 + hAFS-CMHypo + Dox: 
46.37 ± 6.84% of SA β -galactosidase positive cells and 33.80 ± 0.94% of cleaved caspase-3 positive cells, values 
expressed as mean ± s.e.m.; * p < 0.05 (p = 0.0208), * * * * p < 0.0001. (e) Western blot analysis (left panel) and 
corresponding densitometry (right panel) for phosphorylated Akt (Ser473 p-Akt, 60kDa) in untreated mNVCM 
(Ctrl) or mNVCM treated with 1 μ M Dox (Dox), with 40 μ g/ml hAFS-CMHypo (hAFS-CMHypo), or with 20 μ M 
LY-294002 (PI3K inhibitor) followed by 40 μ g/ml hAFS-CMHypo (LY-294002 + hAFS-CMHypo). Full-length blots 
are represented in Supplementary Fig. S4. * * p < 0.01 (p = 0.0011), * * * * p < 0.0001.
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hAFS-CMHypo promotes Dox efflux from mouse neonatal cardiomyocytes. Since pre-incubation 
with the hAFS-CMHypo substantially reduced DNA damage by Dox treatment, we wondered whether the 
hAFS-CMHypo might also affect the retention of the drug by mNVCM besides activating protective pathways. As 
experimental studies have shown that the transmembrane pump ABCB1B extrudes Dox from cells and is critical 
to determine its toxic effects20, we examined the levels of this transporter in mNVCM. Pre-incubation with the 
hAFS-CMHypo led to a sharp increase in Abcb1b expression of about 3-fold and 2-fold, respectively, compared to 
Dox treatment alone or to untreated cells and this was prevented by LY-294002 (Fig. 5a). Since Dox is autoflu-
orescent, the fluorescence in culture medium after treatment with the drug is a function of its efflux from cells. 
This feature was exploited to determine whether Abcb1b modulation reduced Dox accumulation in mNVCM. As 
shown in Fig. 5b, fluorescence in culture medium was significantly higher at 6, 9 and 24 hours after exposure to 
Dox, when cells were pre-incubated with hAFS-CMHypo than when they were not (Fig. 5b). Interestingly, no mod-
ulation of the multidrug resistance gene ABCB1 nor Dox fluorescence in culture medium was observed when the 
human breast cancer cell line MDA-MB-23121, was pre-incubated with hAFS-CMHypo before being treated with 
Dox (Supplementary Fig. S3).
hAFS-CMHypo antagonizes Dox toxicity on human cardiac progenitor cells. Damage, senes-
cence and depletion of human endogenous cardiac progenitor cells (hCPC) are thought to be critical for the 
pathogenesis of Dox cardiomyopathy4,22. Therefore, we assessed whether hAFS-CMHypo may also protect hCPC 
against Dox. hCPC were isolated from human atrial samples as previously described23 and treated with Dox 
with or without prior incubation with hAFS-CMHypo or hNCTC-CMHypo. The frequency of SA β -galactosidase 
positive cells was significantly increased by Dox, as expected, and reduced by 51% by pre-incubation with 
hAFS-CMHypo (50.1 ± 6.4% vs 24.5 ± 1.9% of SA β -galactosidase positive cells), whilst hNCTC-CMHypo was not 
effective (Fig. 6a,b). The same trend was observed when senescence was evaluated by analysing the expression of 
p16INK4a, with hAFS-CMHypo decreasing p16INK4a levels by 30% (2.3-fold increase vs 1.6-fold increase compared 
to untreated cells, Fig. 6c,d). In agreement with the results of previous, similar in vitro studies4,24, Dox induced 
hCPC apoptosis, as assessed by staining for activated caspase-3, to a limited extent (4.5 ± 0.6% vs 0.9 ± 0.1% 
cleaved caspase-3 positive cells, Fig. 6e,f). The rate of apoptosis was even lower when cells were pre-incubated 
with hAFS-CMHypo before exposure to Dox, although not significantly (4.5 ± 0.6% vs 3.8 ± 0.5% cleaved caspase-3 
positive cells with Dox alone vs hAFS-CMHypo + Dox, respectively; Fig. 6e,f). No significant effects on either 
senescence or apoptosis markers were exerted by hAFS-CM or hNCTC-CM alone (see Supplementary Fig. S2).
Discussion
This work provides robust evidence, gathered from the study of different cellular models, that the hAFS secretome 
(hAFS-CM) antagonizes Dox cardiotoxicity. As Dox-induced left ventricular dysfunction and heart failure are 
relatively common and by themselves have clinical burden, cause hospitalization, and carry a risk of mortality1,5, 
our results hold high translational potential value and great promise for future therapeutic strategies.
DNA damage has been pinpointed as the driver of the noxious effects of Dox on cardiomyocytes and CPC10, 
which eventually leads to their senescence and apoptosis6,8,9,17. These cellular alterations are the basis for a car-
diomyopathy that typically has delayed clinical presentation. Although the cardiac cytotoxicity of Dox can be 
observed shortly after first infusion of the drug25, myocardial tissue derangement, cardiac dilatation and decline 
in left ventricular ejection fraction tend to occur towards the end of chemotherapy or thereafter - even years 
Figure 5. The hAFS-CMHypo induces the up-regulation of Abcb1b and the efflux of Dox from mNVCM.  
(a) Real time qRT-PCR showing significant up-regulation of the Abcb1b gene in mNVCM incubated with 40 μg/ml 
hAFS-CMHypo prior to exposure to 1 μ M Dox (hAFS-CMHypo + Dox) compared to untreated mNVCM (Ctrl)  
and mNVCM exposed to Dox (Dox); this effect was significantly reduced when cells were treated with the  
PI3K inhibitor, LY-294002 (LY-294002 + hAFS-CMHypo + Dox); * p < 0.05 (p = 0.0232), * * * * p < 0.0001.  
(b) Quantification of Dox fluorescence in the mNVCM-conditioned medium at 0.5, 1, 2, 3, 6, 9 and 24 h following 
incubation with 40ug/ml hAFS-CMHypo and/or exposure to 1 μ M Dox (mean ± s.e.m.). * * p < 0.01 (p = 0.0058),  
* p < 0.05 (p = 0.0110 and p = 0.0292 for the 9 h and 24 h time point respectively). A.U.: Arbitrary Unit.
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later26,27. Whereas depletion of terminally-differentiated cardiomyocytes is intuitively associated with decreased 
ventricular mass and, thereby, contractile force, senescence of CPC may worsen Dox cardiomyopathy by hin-
dering the intrinsic ability of the myocardium to self-repair and regenerate via the activation of endogenous 
Figure 6. The hAFS secretome antagonizes Dox-elicited damage of human CPC. (a) Representative images 
of human c-kit+ CPC (hCPC) stained for senescence associated (SA) β -galactosidase: untreated cells (Ctrl), cells 
exposed to 0.2 μ M Dox (Dox), and cells incubated with 40 μ g/ml of the hAFS-CMHypo (hAFS-CMHypo + Dox) or 
with the hNCTC-CMHypo (hNCTC-CMNormo + Dox) prior to Dox treatment. Scale bar 100 μ m.  
(b) Percentage of hCPC expressing SA β -galactosidase (mean ± s.e.m.). Ctrl: 14.8 ± 2.7%, Dox: 50.1 ± 6.4%,  
hAFS-CMHypo + Dox: 24.6 ± 1.9%, and hNCTC-CMHypo + Dox: 47.5 ± 7.0%; * p < 0.05 (p = 0.0285).  
(c) Representative western blot for the expression of the senescence marker p16INK4a (17kDa; housekeeping 
GAPDH, 37kDa) after exposure to 0.2 μ M Dox with or without pre-incubation with 40 μ g/ml of the hAFS-
CMHypo or with hNCTC-CMHypo. Full-length blots are represented in Supplementary Fig. S4. (d) Densitometry 
of the western blot for p16INK4a with same conditions as in (c). (e) Representative images of hCPC stained for 
cleaved-caspase-3 (Caspase-3): untreated cells (Ctrl), cells exposed to 1 μ M Dox (Dox), and cells incubated with 
40 μ g/ml of the hAFS-CMHypo (hAFS-CMHypo + Dox) or with the hNCTC-CMHypo (hNCTC-CMNormo + Dox) 
prior to Dox treatment. Scale bar 100 μ m. (f) Percentage of hCPC expressing cleaved caspase-3 (% Caspase-3+ 
cells, mean ± s.e.m.). Ctrl: 0.90 ± 0.1%, Dox: 4.5 ± 0.6%, hAFS-CMHypo + Dox: 3.8 ± 0.5%, and hNCTC-CMHypo 
+ Dox: 6.4 ± 1.5%.
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cardiac progenitors22. Previously published work showed that senescence is more pronounced than apoptosis 
in CPC exposed to Dox and may be primarily responsible for deficient CPC activity, conferring greater sus-
ceptibility to myocardial injury and, eventually, development of anthracycline-related cardiomyopathy4,24. We 
confirmed that Dox strongly triggered CPC senescence and found that hAFS-CM counteracted it; conversely, 
Dox-induced apoptosis of CPC survival was limited and, possibly because of such a small magnitude of effect, it 
was non-significantly decreased by hAFS-CM. Furthermore, hAFS-CM antagonized Dox-initiated DNA damage, 
senescence, and apoptosis of cardiomyocytes. Thus, we conclude that hAFS-CM offsets fundamental and early 
aspects of Dox cardiotoxicity.
In the last decade, many authors have demonstrated that structural and functional improvements obtained 
after engraftment of stem cells into the heart can largely be attributable to secreted factors, collectively indi-
cated as secretome, rather than to the direct trans-differentiation of the exogenous stem cells into cardiovascular 
cells forming new viable tissue28–30. As a consequence, a current paradigm in cardiac regenerative medicine is to 
exploit the stem cell secretome for therapy. In a rat model of ischemia/reperfusion injury, we previously showed 
that systemic injection of hAFS-CM remarkably reduced infarct size in the short term to the same extent as 
administration of hAFS14. The experiments presented here integrate these earlier findings and confirm that, in 
general, the hAFS secretome is a valuable source of cardioprotective factors.
Other authors have reported that both transplantation of embryonic stem cells (ES) and the ES-CM oppose 
Dox-induced cardiomyopathy in mice31–34. Protection against Dox cardiotoxicity via potent paracrine effects has 
also been described for the secretome of mesenchymal stem cells (MSC) derived from either human induced 
pluripotent stem cells (iPS) or from bone marrow35. Overall, these results are consistent with ours and suggest 
that, in principle, the stem cell secretome may be employed to treat Dox cardiac side effects, while avoiding the 
problems related to standard cell therapy, such as immune rejection and teratogenicity. Yet, important limita-
tions with ES and iPS or bone marrow MSC should not be overlooked: ES are not free of ethical constraints, 
and culture of iPS is technically challenging and rather time-consuming. These drawbacks are not encountered 
with adult bone marrow MSC, which, however, are obtained by invasive sampling with low yield and present 
limited self-renewal potential. By contrast, there are no ethical concerns related to hAFS, as they are isolated 
from remaining samples of amniotic fluid collected by amniocentesis for prenatal screening. Moreover, hAFS are 
endowed with remarkable self-renewal capability, ES-like properties - such as proliferative ability and expression 
of pluripotent markers - and a higher paracrine potential than that of adult stem cells. That hAFS are immature 
foetal cells and developmentally very “young”, may go some way to explain their more powerful paracrine poten-
tial than adult stem cells. Finally, they withstand cryopreservation for a long time while maintaining a stable 
karyotype11, which makes their banking and scale up expansion very feasible.
Multiple pathways may mediate the antagonism of Dox toxicity by the hAFS-CM. Here it is suggested a PI3K/
Akt-dependent role for NF-κ B and its target genes, Il6 and Cxcl1. Direct evidence of the involvement of IL-6 and, 
secondarily, CXCL-1 was obtained by using specific blocking antibodies. IL-6 is released by stressed cardiomy-
ocytes and promotes cardiac cell survival in an autocrine/paracrine fashion18. It acts through several intracel-
lular mediators, including PI3K/Akt36,37, which raises the possibility of a feed-forward signalling loop, whereby 
PI3K/Akt promote the transcription of Il6 and IL-6 activates PI3K/Akt. Furthermore, CXCL1, the murine homo-
logue of IL-8, is an established angiogeneic factor38,39 and has been reported to exert anti-inflammatory and 
pro-survival effects in a mouse model of autoimmune myocarditis19. Interestingly, PI3K/Akt activity has repeat-
edly been linked to protection against Dox cardiotoxicity16,40, including by the ES-CM32. In addition, NF-κ B is 
the nexus of one of the functional networks associated with the top 20 factors preferentially overexpressed in 
the iPS-derived MSC-CM, which has also been found to reduce Dox cardiotoxicity35. Hence, the secretomes of 
different stem cell types may have in common at least part of the cellular mechanisms by which they counteract 
Dox cardiac damage. As discussed above, however, compared with the conditioned medium of other stem cells, 
the hAFS-CM has unique characteristics, such as the ease of isolation from discarded clinical samples and the 
high-self renewal capacity in culture, making this cells an ideal source to exploit for future paracrine therapy.
The sensitivity of cardiac cells to Dox is dictated by the balance between drug retention and efflux, the latter 
being largely function of the activity of the transporter, ABCB1B (also known as Multidrug Resistance Protein 1 
or P-glycoprotein). In cardiomyocytes, both induction of this gene by exogenous stimuli41, and overexpression 
via genetic construct42, confer resistance to Dox injury. Moreover, in patients there is a correlation between pol-
ymorphisms in ABCB1B and susceptibility to anthracycline cardiotoxicity43. We now report that the hAFS-CM 
also promotes Abcb1b transcription via PI3K/Akt and, as a consequence, Dox extrusion from cardiomyocytes. 
Remarkably, it has recently been demonstrated that NF-κ B, which is recruited by the hAFS-CM, is a positive 
regulator of Abcb1b expression20. This work did not aim to evaluate the effects of hAFS-CM on cancer cells. 
Nonetheless, it is worth noting that in a human breast cancer cell line the hAFS-CM did not modulate ABCB1 
levels or Dox efflux, indicating that, at least in some tumour cell types, Dox metabolism is not enhanced by 
hAFS-CM. In terms of the prospect of a future therapeutic use of the hAFS secretome, this finding is reassuring.
We acknowledge that the present study has limitations. The data obtained with the embryonic H9c2 car-
diomyoblasts and neonatal cardiomyocytes (mNVCM) were not replicated with mature adult cardiomyocytes. 
Since these cell types correspond to different stages of development and, thereby, display substantial phenotypic 
differences, this aspect may be especially relevant from a translational point of view and needs further evaluation. 
Furthermore, the effects of sustained incubation of cardiomyocytes and CPC with hAFS-CM need to be inves-
tigated, in order to define the optimal duration of treatment for possible therapeutic application. In addition, 
in vivo experiments are needed to investigate the effects of the hAFS-CM on mature adult cardiomyocytes and 
CPC in vivo while within their own microenvironment, which comprises other cell types possibly influenced by 
the hAFS-CM.
As far as the mechanisms of the hAFS-CM paracrine cardioprotection are concerned, it is likely that other sig-
nalling pathways, besides PI3K/Akt and a set of NF-κ B responsive genes, contribute to the hAFS-CM prevention 
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of Dox toxicity. Furthermore, detailed characterization of hAFS-CM composition is essential to pinpoint the solu-
ble factors that specifically mediate the inhibition of Dox DNA damage, senescence, and apoptosis. Finally, a more 
detailed analysis of the possible influence of donor age on the hAFS secretome is required to understand whether 
there may be significant variability between cell batches obtained from different women. Indeed, in our study, we 
used the secretome of different hAFS obtained by pooling together amniotic fluid samples from 3 different donors 
in order to limit possible variations of donor age on cell proliferation.
In conclusion, we prove, in principle, that the hAFS secretome protects cardiomyocytes and CPC against Dox 
toxicity. These results substantiate the concept of a stem cell based paracrine approach via cell-free delivery of 
bioactive factors to prevent cardiotoxicity of Dox and possibly other anticancer agents. Such a treatment might 
be especially important for survivors of childhood cancer, in whom cardiac complications of chemotherapy can 
significantly curtail life expectancy. In addition, the data presented herein may lay the foundations for future 
research work, using the hAFS secretome as an easily obtainable and appealing source of paracrine cardioactive 
molecules that may become an advanced medicinal product for new cardiac regeneration strategies, without some 
of the ethical and technical limitations associated with embryonic and adult stem cell use.
Methods
Cell culture. hAFS were sorted for c-kit expression (CD117 MicroBead Kit, Miltenyi Biotechnology) within 
the cells isolated from left over samples of II trimester amniotic fluid, collected via prenatal screening amniocen-
tesis, with informed consent from donors and proved negative for disease11,44,45. The protocol complied with the 
Helsinki Declaration and was approved by the local ethical committee Comitato Etico Regionale IRCCS AOU 
San Martino – IST (protocol 0036463/15 P.R. 428REG2015). Cells were cultured in Minimal Essential Medium 
(MEM) alpha with 15% fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin/streptomycin, (Gibco-Thermo 
Fisher Scientific), 18% Chang B, and 2% Chang C (Irvine Scientific) at sub-confluence. To limit the intrinsic 
variability of primary cultures, which might be influenced by the donors different age (samples were obtained by 
women from 25 up to 46 years old, mean: 38.4 ± 3.3 years old), 3 different human amniotic fluid samples were 
pooled together to isolate hAFS for each experiment.
The NCTC 2544 cell line was purchased from the Interlab Cell Line Collection (Genova, Italy) and cultured in 
MEM/Earl’s Balanced Salt Solution (MEM/EBSS) with 10% FBS, 1% non-essential aminoacids, 1% L-glutamine, 
and 1% penicillin/streptomycin (all EuroClone).
The H9c2 cell line was bought from the European Collection of Authenticated Cell Cultures (Salisbury, UK) 
and cultured as already described15,16.
mNVCM were isolated via enzymatic digestion from 2-day-old C57/Bl6 mouse heart by multiple diges-
tions in a collagenase II solution (300 U/ml, Worthington Biochemicals), according to46, and seeded on gela-
tin (1% solution, Sigma-Aldrich) coating at 105 cells/cm2 in culture medium (69% Dulbecco′ s Modified Eagle 
Medium, DMEM, 15% M199, 10% horse serum, 5% FBS, 1% penicillin/streptomycin and 1% L-glutammine, 
Gibco-Thermo Fisher Scientific). All animal procedures were carried out in compliance with national and 
international laws and specific authorisation (protocol 792/2015-PR from Animal Facility of IRCCS AOU San 
Martino-IST).
The MDA-MB-231 human breast cancer (adenocarcinoma) cell line was purchased from the American Type 
Culture Collection (ATCC, Virginia, US) and cultured in RPMI 1640 medium (Thermo Fisher) supplemented 
with 10% FBS, 1% non-essential aminoacids, 1% L-glutamine, and 1% penicillin/streptomycin (all EuroClone).
hCPC were isolated as previously described23 from human auricolae fragments, obtained following written 
informed consent from patients, in compliance with the Helsinki Declaration and upon approval of the local 
ethical committee IRCCS Istituto Europeo di Oncologia and Centro Cardiologico Monzino (protocol CCFM 
C9/607). Briefly, the myocardial tissue was repeatedly digested at 37 °C in a 3 mg/ml collagenase solution (Serva), 
cells were FACS-sorted (FACSAria, Beckton-Dickinson) for c-kit expression using an APC-conjugated antibody 
(anti-CD117, clone YB5.B8; BD Biosciences) and cultured in Ham’s F12 medium (Lonza) with 10% FBS (Thermo 
Fisher Scientific), 2 mM L-glutathione and 5 × 10−3 U/mL human erythropoietin (both Sigma-Aldrich), 10 ng/mL 
bFGF (Peprotech), and antibiotics (Lonza).
Collection of hAFS-CM and hNCTC-CM. A schematic of hAFS-CM collection is shown in Supplementary 
Fig. S1. hAFS and NCTC 2544 cells were cultured for 24 hours in serum-free medium (SF: MEM alpha medium 
for hAFS and MEM/EBSS for NCTC 2544, both with 1% L-glutamine and 1% penicillin/streptomycin) in nor-
moxia (20% O2 and 5% CO2 at 37 °C) or hypoxia (1% O2 and 5% CO2 at 37 °C in an hypoxic workstation, Baker 
Ruskinn, Carlibiotec s.r.l.). The hAFS-CMNormo, hAFS-CMHypo, hNCTC-CMNormo and hNCTC-CMHypo were con-
centrated 20 times using ultrafiltration membranes with a 3 kDa selective cut-off (Amicon Ultra-15, Millipore). 
Protein concentration was measured by Bradford assay. Samples were stored at − 80 °C until use. At least 3 differ-
ent batches of hAFS-CM and hNCTC-CM were used for each experiment.
Experiment outline. hAFS-CM was used at 40 μ g/ml, this concentration being the most protective in pre-
liminary experiments with H9c2 cardiomyoblasts. The hNCTC-CM was employed at the same concentration. 
Cells were pre-incubated with hAFS-CM or hNCTC-CM for 3 hours prior to exposure to Dox. Apoptosis and cell 
viability were measured after Dox treatment (1 μ M) for 21 hours. Blocking experiments were performed by add-
ing 0.025  μ g/ml anti-IL-6 and/or 0.25  μ g/ml anti-CXCL1 antibodies (clone MP5-20F3 and 48415, respectively, 
R&D Systems) at the end of the 3 hour-incubation with the hAFS-CM when Dox treatment began, or 9 hours after 
hAFS-CM incubation, i.e. 6 hours after starting Dox treatment. Apoptosis was then evaluated 21 hours after Dox 
exposure. Senescence was examined after 3 hours of Dox exposure (H9c2: 0.1 μ M, mNVCM and hCPC: 0.2 μ M) 
followed by 42 hours in complete medium. DNA damage and gene expression profile were evaluated 6 hours after 
treatment with Dox (1 μ M), whereas nuclear translocation of NF-κ B was assessed after Dox (1 μ M) incubation 
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for 1.5 hours. To determine the acute effect on Akt phosphorylation, mNVCM were treated for 10 minutes with 
the hAFS-CMHypo, with or without pre-treatment with LY-294002 (20 μ M, Sigma-Aldrich) for 1 hour. Before 
every experiment, cells were incubated in low-serum culture medium (DMEM low-glucose with 0.5% FBS, 1% 
L-glutamine, and 1% penicillin-streptomycin) for 1 hour. Treatment outline is shown in Supplementary Fig. S1.
Evaluation of senescence and apoptosis. To reveal SA β -galactosidase activity, cells were fixed in glu-
taraldehyde (0.5%) and incubated overnight at 37 °C in a solution containing citric acid (10 mM), potassium 
ferricyanide (5 mM), NaCl (150 mM), MgCl2 (2 mM), and 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside 
(1 mg/ml, all Sigma Aldrich)47. Senescence of mNVCM was also revealed by immunostaining using a primary 
rabbit polyclonal antibody against p16INK4a (Proteintech), followed by Vectastain secondary antibody, horseradish 
peroxidase (HRP)-streptavidin, and 3,3′ -diaminobenzidine (all from Vector Laboratories) as detection system. 
Apoptosis was assessed by immunocytochemistry, using a rabbit monoclonal anti-cleaved caspase-3 antibody 
(clone 5A1E, Cell Signaling Technologies). The percentage of SA β -galactosidase, p16INK4a and cleaved caspase-3 
positive cells was evaluated considering six random fields (20x), taken with the Leica Q500 MC Image Analysis 
System (Leica).
Cell viability assay. Following Dox exposure with or withour hAFS-CM or hNCTC-CM pre-incubation, 
MTT solution (250 μ g/ml; Sigma-Aldrich) was added to the cells for 4 hours and absorbance read at 570 nm on a 
VersaMax (GE Intelligent Platforms) plate reader.
Assessment of DNA damage. After exposure to Dox (1 μ M) with or without pre-treatment with the 
hAFS-CMHypo, mNVCM were fixed in paraformaldehyde solution (4%, Sigma Aldrich) and incubated with a 
rabbit monoclonal antibody against γ H2aX (Ser139, clone 20E3, Cell Signalling Technologies) followed by Alexa 
Fluor488-conjugated secondary antibody (Thermo Fisher Scientific). Fluorescence emission was quantified using 
an Infinite 200 PRO plate reader (Tecan). Immunocytochemistry, immunofluorescence and cell culture images 
were acquired with an Axiovert microscope equipped with Axiovision software (Carl Zeiss).
Gene expression profiling. The gene expression profile of mNVCM treated with Dox (1 μ M) with or 
without pre-incubation with the hAFS-CMHypo, was analysed by Affymetrix MG 430.2 microarray technology. 
Total RNA was extracted using the RNeasy Micro Kit (Qiagen). cRNA for hybridization was prepared using the 
GeneChip® 3′ IVT PLUS Reagent Kit following the instructions provided by Affymetrix. Hybridisation and scan-
ning were performed by standard procedures, as recommended by Affymetrix. Data were deposited in the Gene 
Expression Omnibus repository (www.ncbi.nlm.nih.gov/geo/, accession number: GSE74513) and pre-processed 
using the RMA algorithm with quantile normalization48. Differentially expressed genes were identified apply-
ing a threshold of two-fold increase or decrease of the expression values when comparing the two conditions. 
Enrichment of functional categories of genes was analyzed by EnrichR Gene Set Enrichment Analysis (http://
amp.pharm.mssm.edu/Enrichr/)49.
Real-time quantitative RT-PCR analysis. Total RNA from mNVCM and MDA-MB-231 cells was 
extracted using Qiazol Lysis Reagent (Qiagen) and cDNA obtained using the iScriptTM cDNA Syntesis Kit 
(Bio-Rad). Real-time qRT-PCR was carried out on a 7500 Fast Real-Time PCR System (Thermo Fisher Scientific) 
using Syber Green Master Mix (Thermo Fisher Scientific). Primer sequences for mouse Il6, Cxcl1, Abcb1b, Hprt, 
and human ABCB1 and GAPDH were designed using the NCBI Primer-Blast tool (http://www.ncbi.nlm.nih.gov/
tools/primer-blast/; see Supplementary Table S2 for sequences). Gene expression levels were normalized using 
Hprt or GAPDH as endogenous control by applying the 2−ddCt method.
Western blot. Whole cell lysates were separated on a tris-glycine gel (8–16%, Thermo Fisher Scientific), 
transferred onto a poly-vinylidene difluoride membrane (Bio-Rad), and incubated overnight with the following 
primary antibodies: anti-phosphorylated Akt (Ser473 rabbit monoclonal, clone D9E; Cell Signaling Technologies); 
anti-Akt (rabbit polyclonal, cone 11e7 Cell Signalling Technologies); anti-phosphorylated Iκ Bα (Ser32/36 mouse 
monoclonal, clone 5A5, Cell Signalling Technologies); anti total-Iκ Bα (mouse monoclonal, clone 112B2, Cell 
Signalling Technologies); and anti-p16INK4a (rabbit polyclonal, Proteintech). The membrane was incubated with 
goat anti-rabbit or anti-mouse HRP-conjugated secondary antibodies (sc-2030 and sc-2005, respectively; Santa 
Cruz Biotechnology). Bands were detected by Clarity Western ECL Substrate (Bio-Rad), imaged using Alliance 
LD2 system and software (UVItec), and quantified by densitometry analysis with ImageJ software (NCBI). Values 
were normalized against those of GAPDH, as revealed by a primary antibody directly conjugated to HRP (clone 
D16H11, Cell Signalling Technologies).
Quantification of nuclear levels of NF-κB. Cells were first lysed in an hypotonic solution containing 
Tris-HCl (20 mM), NaCl (10 mM), MgCl2 (3 mM), PMSF (1 mM), and 1x PIC (all Thermo Fisher Scientific) in 
order to separate the cytoplasmic and nuclear fractions. Nuclear proteins were then retrieved by disrupting the 
nuclear fraction in an extraction buffer (1 mM Tris pH 7.4, 2 mM Na3VO4, 100 mM NaCl, 1 mM EDTA, 10% glyc-
erol, 1 mM NaF, 0.5% deoxycholate, 20 mM Na4P2O7, and 0,5% NP40), and quantified by means of Bio-Rad pro-
tein assay (Bio-Rad). Levels of nuclear p65 were assessed using a NF-κ B p65 ELISA kit (Thermo Fisher Scientific).
Measurement of Dox fluorescence in culture medium. mNVCM and MDA-MB-231 cells were 
treated as described above. Their conditioned medium was collected at 0.5, 2, 4, 8, 16 and 24 h after Dox admin-
istration and immediately evaluated for fluorescence emission on a Infinite reader M200 (Tecan) equipped with a 
530/25 nm excitation and a 590/20 nm emission filter (Dox excitation/emission peak).
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Statistical analyses. Results are presented as mean ± s.e.m. of at least three (n = 3) independent rep-
licated experiments. Comparisons were drawn by two-way ANOVA (fluorescence intensity of the mNVCM- 
and MDA-MB-231-conditioned medium after exposure to Dox with or without pre-incubation with the 
hAFS-CMHypo) or one-way ANOVA followed by post-hoc Tukey’s multiple comparisons test (all other data). 
Statistical analysis was performed using GraphPad Prism Version 6.0a (GraphPad Software) with statistical sig-
nificance set at p < 0.05.
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